Beam Therapeutics (BEAM) Long-Term Debt Issuances (2020 - 2026)
Beam Therapeutics (BEAM) posted quarterly Long-Term Debt Issuances of $93.9 million for Q1 2026, up 5617.78% quarter-over-quarter from $1.6 million in Q4 2020.
Powered by 
Analysis
Beam Therapeutics (BEAM) Long-Term Debt Issuances (2020 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Long-Term Debt Issuances for 2 consecutive years, with $93.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $93.9 million; the TTM figure through Mar 2026 stood at $95.5 million (changed N/A YoY), while the FY2020 annual figure was $3.3 million, down 47.12% from the prior year.
- Long-Term Debt Issuances grew to $93.9 million in Q1 2026 per BEAM's latest filing, from $1.6 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $93.9 million in Q1 2026 and bottomed at $93.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | - |